This phase 3 trial is evaluating the effectiveness of using two targeted therapies (GKS3359609 and pembrolizumab) to treat patients with recurrent or metastatic head and neck squamous cell carcinoma
Cancer type : Head and neck
This phase III trial is comparing two combination treatments with a chemoimmunotherapy (as chosen by the investigator) in patients with newly diagnosed Chronic Lymphocytic Leukaemia
Cancer type : Blood
This phase III trial will compare the safety and effectiveness of two targeted cancer drugs in patients with HER-2 positive, invasive breast cancer following neoadjuvant therapy
Cancer type : Breast
This phase III trial is trying to improve maintenance therapy for patients with stage 3B or 4 non-small cell lung cancer who have remained stable or responded to first-line treatment. It will compare immunotherapy alone and in combination with an oral targeted therapy.
Cancer type : Lung
This phase III trial is trying to understand how well three targeted cancer drugs work on their own or together to treat patients with EGFR+ non-small cell lung cancers that have spread to other parts of the body
Cancer type : Non-Small Cell Lung Cancer
This phase III trial is trying to understand how well two targeted cancer drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer, compared to standard of care chemotherapy
Cancer type : Urothelial
This phase III trial is trying to understand whether to give glioblastoma patients chemotherapy as soon as possible following surgery and prior to chemoradiotherapy; and how many cycles of standard adjuvant chemotherapy to give patients after chemoradiotherapy
Cancer type : Brain and Spinal
This phase III trial is trying to demonstrate the benefits of adding the oral drug, Debio 1143, to chemoradiotherapy (CRT) treatment in patients with locally advanced squamous cell carcinoma of the head and neck
Cancer type : Head and Neck
This phase III trial is comparing survival outcomes for patients with high-risk cutaneous squamous cell carcinoma who are treated with adjuvant immunotherapy (cemiplimab), compared to those who are treated with a placebo, after surgery and radiotherapy
Cancer type : Skin
This phase III trial is comparing the safety and effectiveness of a type of targeted therapy, with a type of chemotherapy, for the treatment of advanced non-squamous non-small cell lung cancer that has progressed, despite previously being treated
This phase I trial is evaluating the safety and tolerability of a new type of immunotherapy, given alone or with standard of care treatment, in patients with PD-L1 non-small cell lung cancer
This phase III trial is trying to determine whether the combination of two immunotherapy drugs (nivolumab and ipilimumab) is effective in preventing cancer recurrence in patients with renal cell carcinoma, who have had part or all of their kidney removed
Cancer type : Urinary System
This phase III trial will evaluate the safety and effectiveness of a type of immunotherapy, given in combination with chemotherapy (Arm A) or a type of targeted therapy (Arm B), in patients with multiple myeloma who have got worse or not responded to earlier treatment
Cancer type : Multiple Myeloma
This phase III trial is trying to understand if adding a targeted therapy drug to a new type of chemotherapy will help patients with HER2-positive breast cancer that has spread to other parts of the body or is unable to be surgically removed
This phase III trial is trying to understand whether an oral targeted therapy (capmatinib) is able to control lung cancer better than standard chemotherapy (docetaxel) and is safe to use in patients with lung cancer
This phase III trial is evaluating the safety and effectiveness of a targeted adjuvant therapy in patients with stage 2 or 3 non-small cell lung cancer who have had their cancer removed or treated with curative intent
This phase III trial is comparing the safety and effectiveness of a single drug treatment (belantamab mafodotin or blenrep) and a chemotherapy (pomalidomide plus low dose dexamethasone) for the treatment of patients with relapsed or refractory multiple myeloma
This phase III trial is testing the addition of a targeted therapy drug to treatment for previously untreated patients with intermediate-very high risk myelodysplastic syndromes (MDS)
Cancer type : Myelodysplasia
This phase I trial is trying to understand how safe and tolerable a new intravenous cancer drug (RO7283420) is for the treatment of Acute Myeloid Leukaemia (AML)
This phase III trial is trying to understand whether adding a form of targeted therapy to standard chemotherapy will improve overall survival for patients with non-small cell lung cancer
This phase III trial is comparing the safety and effectiveness of a targeted therapy and standard chemotherapy for the treatment of patients with high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube cancer
Cancer type : Female Reproductive System
This phase III trial will assess the safety and effectiveness of a targeted cancer drug, given in combination with chemotherapy and followed by maintenance therapy, in patients with advanced or recurrent endometrial cancer
This phase III trial will add a type of immunotherapy to chemotherapy treatment in patients with recurrent or metastatic squamous cell carcinoma of the anal canal, to see if it is more or less effective than using chemotherapy on its' own
Cancer type : Anus
This phase III trial is evaluating whether targeted therapy, alone or in combination with chemotherapy, is more effective than standard care in patients with metastatic colorectal (bowel) cancer
Cancer type : Colorectum
This phase II trial is evaluating an oral drug (Talazoparib) in men who have previously received treatment for metastatic Castration-Resistant Prostate Cancer (CRPC)
Cancer type : Prostate
This phase II trial is evaluating nab-paclitaxel in combination with carboplatin as a first line treatment for gastrointestinal neuroendocrine cancer
Cancer type : Stomach
In this phase II trial, patients with severe aplastic anaemia who have been treated with, but not responded to immunosuppressive therapy (IST), will receive a new drug (avatrombopag) as a potential treatment for their condition
Cancer type : Aplastic Anaemia
This phase II trial is trying to understand whether the addition of a new drug (avatrombopag) to standard immunosuppressive therapy (IST) can effectively treat patients with severe aplastic anaemia who have not had prior treatment
This phase III trial is evaluating the safety and effectiveness of a targeted therapy in patients with chronic lymphocytic leukaemia
This Phase III trial will be comparing two oral therapies (Zanubrutinib versus Ibrutinib) in patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma that has got worse or not responded to prior treatment
This phase I trial is evaluating two drugs (one oral and one intravenous) in Acute Myeloid Leukaemia (AML) patients who have got worse or not responded to treatment
Cancer type : Acute Myeloid Leukaemia
This phase II trial is evaluating Obinutuzumab alone and in combination with a new oral drug (BGB-3111) for the treatment of non-Hodgkin follicular lymphoma that has got worse or not responded to prior treatment
Cancer type : Follicular Lymphoma
This phase III trial is comparing conventional-dose chemotherapy (TIP regimen) with high-dose chemotherapy plus an autologous stem cell transplant (TI-CE regimen) as initial salvage treatment for patients with germ cell tumours that have got worse or not responded to prior therapies
This phase III trial is trying to determine how safe and effective the drug Uproleselan is, when given in combination with chemotherapy, in the treatment of Acute Myeloid Leukaemia that has got worse or not responded to prior therapy
This phase I/II trial is evaluating a new type of immunotherapy (CTX110) in patients with B-Cell malignancies (Non-Hodgkin Lymphoma) that have got worse or not responded to prior treatment
This phase I trial is evaluating the safety and dose of a new oral drug (CPI-818) in patients with T-Cell Lymphoma who have got worse or not responded to prior treatment
Cancer type : T-Cell Lymphoma
This phase II trial is testing the safety and activity of a targeted therapy (REGN1979) in patients with Follicular Lymphoma that has got worse or not responded to prior treatment(s)
This phase Ib trial is assessing the safety of a new drug (blinatumomab) for the treatment of indolent Non-Hodgkin's Lymphoma that has got worse or not responded to prior therapy
This phase I/II trial is evaluating a combination of two intravenous drugs (Isatuximab and Cemiplimab) for patients with multiple myeloma that has got worse or not responded to prior treatment
This phase I trial will assess the safety and effectiveness of a new type of immunotherapy, known as CAR T-cell therapy, in patients with advanced renal cell carcinoma that has got worse or not responded to prior treatment
This phase I trial is evaluating a targeted therapy, given orally to patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome that has got worse or not responded to prior treatment
This phase II trial is testing an investigational drug (INCB050465) in patients with Diffuse Large B-Cell Lymphoma that has got worse or is not responsive to treatment
This phase I trial is evaluating a new targeted cancer drug in patients with Non-Hodgkin's Lymphoma who have got worse or not responded to prior treatment
This phase II trial is evaluating the safety and effectiveness of an immunotherapy treatment in patients with B-Cell Non-Hodgkin Lymphoma that has got worse or not responded to prior treatment
This phase I trial is evaluating the use of an oral drug (Ibrutinib) in combination with donated immune cells in patients with EBV-positive lymphomas that have not responded, got worse or are not suitable for standard treatments
This phase III trial is comparing the effectiveness of two treatments (chemotherapy + immunotherapy, versus the best available therapy) in myelofibrosis patients who have got worse or not responded to previous treatment
This phase I trial is trying to determine the recommended dose of a new intravenous therapy (AMG 427) in patients with Acute Myeloid Leukaemia that has got worse or not responded to prior therapies
This phase III trial is comparing the safety and effectiveness of two targeted cancer therapies, given in combination with a standard cancer treatment, for patients with multiple myeloma that has got worse or come back following prior treatment
This phase I/II trial is testing an immunotherapy alone and in combination with other anti-cancer treatments in patients with multiple myeloma who have got worse or not responded to earlier treatment
This phase II trial is measuring the safety and recommended dose of an immunotherapy drug (GSK2857916) in combination with another cancer drug (Bortezomib or Lenalidomide) and a steroid for the treatment of multiple myeloma that has got worse or is not responsive to other treatments
This phase I trial is testing two different ways to give an immunotherapy drug (isatuximab) to patients with Multiple Myeloma, who have got worse or not responded to prior treatment
This phase II trial is trying to understand how effective a new targeted therapy is in Hodgkin's Lymphoma patients whose cancer has got worse or not responded to previous treatment
This phase I trial is evaluating the safety and effectiveness of an investigational therapy (BTCT4465A) alone and in combination with an immunotherapy drug (Atezolizumab) in patients with B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia who have got worse or not responded to treatment
This phase I/II trial is trying to understand how much targeted therapy is required and if it is safe to use for the treatment of B-cell lymphoma that have got worse, not responded or come back on prior treatments
This phase I trial is evaluating the safety and effectiveness of two targeted therapy drugs, each given in combination with chemotherapy for the treatment of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) that has got worse or not responded to prior treatment
This early Phase I trial is evaluating a new drug (AMG 673), administered intravenously to patients with Acute Myeloid Leukaemia (AML) that has got worse or come back following prior therapy
This phase I trial will begin to understand the safety and effectiveness of a new form of immunotherapy for the treatment of patients with multiple myeloma who have not responded or got worse using previous treatment
This phase I trial will begin to understand how safe and tolerable an intravenous cancer drug (ABBV-467) is for the treatment of multiple myeloma in patients who have not responded or got worse on previous treatment
This phase III trial is comparing the use of an oral cancer drug (Lenalidomide) alone and in combination with chemotherapy (Selinexor) and a corticosteroid (Dexamethasone) in patients with newly diagnosed multiple myeloma who are currently undergoing Autologous stem cell transplant
This phase I trial is trying to determine the safety and recommended dose of an immunotherapy, combined with standard of care treatment, in patients with newly diagnosed multiple myeloma
This phase I/II trial will begin to understand how safe, well tolerated and effective a combination therapy is for the treatment of BRAF-mutant melanoma that has spread to other parts of the body
Cancer type : Melanoma (Skin)
This phase I trial is evaluating an oral anti-cancer drug (arsenic trioxide) as a consolidation therapy for acute promyelocytic leukaemia (APML)
This phase I/II trial is evaluating an oral drug (FT-2102) alone and in combination with a chemotherapy drug (Cytarabine or Azacitidine) in patients with Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome
This Phase II trial is evaluating the combination of an immunotherapy (Pembrolizumab) and a targeted therapy (Denosumab) for the treatment of advanced clear cell renal cell carcinoma (ccRCC)
This Phase III trial is comparing an anti-HER2-antibody drug with standard of care therapy in patients with pre-treated, HER2-positive breast cancer that has spread to other parts of the body
This phase IB/II trial is evaluating the safety and effectiveness of using current standard of care treatment in combination with novel targeted therapies to treat metastatic microsatellite-stable colorectal cancer
This phase I/II trial will be comparing different doses of the drug AMG 701 in patients with Multiple Myeloma
This phase III trial is trying to determine whether it is effective to give tranexamic acid (a drug that reduces heavy bleeding) to patients with Thrombocytopenia
This phase I trial is evaluating the investigational drug, venetoclax, in combination with chemotherapy for the treatment of Acute Myeloid Leukaemia (AML)
This phase II trial is trying to determine if a new immunotherapy (Blinatumomab) can help treat patients with Acute Lymphoblastic Leukaemia
Cancer type : Acute Lymphoblastic Leukaemia
This phase I trial is evaluating the safety and effectiveness of a new oral drug (TG-1701) for patients with B-cell malignancies that have not responded or gotten worse with prior treatments
This phase I/II trial is evaluating an immunotherapy combination (MK-4280 and Pembrolizumab) in patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell Lymphoma
This phase II trial is assessing the safety and effectiveness of using targeted therapy and chemotherapy to treat fit patients with previously untreated mantle cell lymphoma, with or without a stem cell transplant and further maintenance therapy
Cancer type : Mantle Cell Lymphoma
This phase III trial is trying to understand whether it is safer and more effective to combine chemotherapy and targeted therapy for the treatment of mantle cell lymphoma, or to use targeted therapy alone, in patients who are not eligible for a stem cell transplant and have not received prior treatment
This phase III trial will assign patients with follicular lymphoma to a certain type of treatment using a PET-scan and assess overall outcomes associated with treatment
This phase II trial is evaluating the effects of a new drug on anemia, in patients who have very low, low or intermediate risk Myelodysplastic Syndromes (MDS)
This phase III trial is evaluating the safety and effectiveness of a chemotherapy in combination with a cancer treatment known as Azacitidine (Vidaza) in patients with newly diagnosed higher-risk myelodysplastic syndrome
This phase III trial is investigating the safety and effectiveness of two types of targeted therapy in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS)
This phase II trial is investigating different chemotherapy combinations for the treatment of elderly patients that have Acute Myeloid Leukaemia
This phase I trial is trying to understand how a new intravenous drug works, and if it is safe and tolerable to use, in the treatment of patients with multiple myeloma
This phase 1 trial evaluates the safety and tolerability of a targeted therapy (MEDI2228) for patients with recurrent Multiple Myeloma.
This phase I/II trial is looking at the most appropriate treatment approaches for patients with newly diagnosed multiple myeloma, taking into consideration patient frailty (weakness)
This trial is evaluating the effectiveness of a targeted therapy (Isatuximab) for patients with newly diagnosed multiple myeloma, who are unable to have a transplant and have had an inadequate response to treatment with lenalidomide and dexamethasone
This phase III trial is trying to find the recommended dose of a targeted therapy that may benefit patients who have high-risk smouldering multiple myeloma
This phase I/II trial will begin to understand how effective a combination therapy (BelaMafKd) is for the treatment of relapsed or refractory multiple myeloma
This phase III trial is trying to determine the overall survival of patients with hepatocellular (liver) cancer who receive two types of immunotherapy (nivolumab plus ipilimumab) versus those who receive standard care (targeted therapy with sorafenib or lenvatinib)
Cancer type : Liver
This phase III trial is combining two oral drugs (Ibrutinib and Venetoclax) for the treatment of Mantle Cell Lymphoma
This phase I/II trial has been designed to find the recommended dose of a targeted therapy drug and determine whether it is more effective than chemotherapy as treatment for multiple myeloma
This phase III trial has been designed to evaluate the addition of two cancer treatments (venetoclax in combination with azacitidine) to standard care, compared with standard care on its' own as a maintenance therapy for adult's with acute myeloid leukaemia (AML)
This phase IV trial is comparing the outcomes of continuing or discontinuing pexidartinib treatment in patients that have previously received treatment for tenosynovial giant cell tumours
Cancer type : Germ cell tumour
This phase I trial will evaluate different doses of a new cancer drug (RO7425781) for the treatment of multiple myeloma patients who cannot tolerate other treatment options or for whom no standard treatment is available
This phase II/III trial is comparing two intravenous drugs (Irinotecan liposome injection and Topotecan injection) in patients with small cell lung cancer who have gotten worse after first line therapy
This phase II trial is evaluating an oral drug (KRT-232) for the treatment of patients with myelofibrosis who are no longer benefiting their current treatment with a JAK inhibitor
This phase I/II trial is trying to find the maximum tolerated dose of a new intravenous cancer drug (AZD2811) as a monotherapy or combination-treatment for acute myeloid leukaemia (AML)
This phase III trial is comparing a type of immunotherapy, called CAR-T therapy, with two forms of standard treatment for multiple myeloma
This phase I trial is evaluating the combination of a new intravenous drug (S64315) and an oral chemotherapy drug (venetoclax) in patients with Acute Myeloid Leuakemia (AML)
This phase III trial is combining two drugs (Pracinostat and Azacitidine) in patients with newly diagnosed Acute Myeloid Leukaemia (AML)
This phase I trial evaluates effectiveness, safety and tolerability of the targeted therapy (AMG 397) for the treatment of patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Acute Myeloid Leukaemia
This phase I trial will evaluate whether stereotactic ablative radiotherapy (SABR) is a safe and effective treatment option for patients with non-small cell lung cancer (NSCLC) whose cancer is large and/or has spread to the nearby lymph nodes
This phase III trial is trying to understand whether it is more or less effective to use hormone therapy alone or in combination with a targeted cancer drug for the treatment of advanced HR+/HER2- breast cancer that has gotten worse or come back on prior treatment
This phase II trial is trying to understand whether using a type of immunotherapy (Nivolumab) before starting standard chemotherapy will have a different effect on reducing tumour size for patients with early stage triple negative breast cancer, compared to if the immunotherapy and chemotherapy were given at the same time
This phase III trial is testing the oral drug, regorafenib, for the treatment of refractory and advanced gastro-oesophageal cancers
This phase III trial is evaluating an investigational drug (Sutimlimab) in patients with primary cold agglutinin disease without a recent history of blood transfusion
This phase III trial is evaluating the safety and effectiveness of using a combination of a targeted therapy (Pembrolizumab) and an anti-hormonal therapy (Enzalutamide) to treat patients with metastatic castration-resistant prostate cancer.
This phase III trial is evaluating the effectiveness and safety of chemotherapy (carboplatin and paclitaxel) in combination with two targeted therapies (Pembrolizumab and Olaparib) to treat women with epithelial ovarian, fallopian tube or primary peritoneal cancer.
This phase III trial will assess an adjuvant immunotherapy in children and adults who have completed surgery for Stage IIB/C melanoma and have a high risk of their cancer coming back
This phase I trial is evaluating an oral drug (BGB-3111) in combination with another drug (obinutuzumab) for the treatment of B-Cell Non Hodgkin Lymphoma
This phase I trial is evaluating an intravenous drug (BFCR4350A) in patients with multiple myeloma, who have progressed or not responded to prior treatment
This phase I trial is evaluating the safety of a new antibody-targeting therapy (TG-1801) in patients with B-Cell Lymphoma
This phase II trial is evaluating an investigational antibody therapy (KappaMab) in combination with lenalidomide (a chemotherapy drug) and dexamethasone (a steroid) for the treatment of relapsed Multiple Myeloma
This phase I trial is evaluating an investigational drug (AMG 176) in patients with Multiple Myeloma
This phase III trial is adding the investigational drug copanlisib, to standard immunochemotherapy (R-B or R-CHOP) for patients with Non Hodgkin Lymphoma
This phase II trial is assessing an induction therapy (VCD) alone and with daratumumab maintenance (VCDD) as a treatment alternative for Multiple Myeloma patients who are unable to receive a transplant
This phase III trial is combining elotuzumab with three other drugs (cyclophosphamide, thalidomide and dexamethasone ) for the treatment of Multiple Myeloma
This phase II trial is investigating the role of the drug sorafenib, given in combination with intensive chemotherapy for the treatment of Acute Myeloid Leukaemia (AML)
This phase III trial is comparing the effectiveness of two targeted therapies as a first line treatment for newly diagnosed Acute Lymphoblastic Leukaemia (ALL) in combination with reduced-intensity chemotherapy
This phase III trial is comparing the clinical benefit of two oral therapies (momelotinib versus danazol) in adults with myelofibrosis
This phase III trial is trying to determine whether a new self-administered therapy (Fedratinib) is safer and more effective than the current best available therapy in the myelofibrosis treatment
Cancer type : Myelofibrosis
This study is looking at circulating DNA and how it could inform adjuvant chemotherapy for recurrence-free survival in patient with stage II colon cancer
Cancer type : Bowel
This phase III trial is comparing the safety and effectiveness of two oral hormone therapy drugs in patients with ER+, HER2- breast cancer that has spread locally or to other parts of the body
This phase I trial is studying a new oral cancer drug in combination with immunotherapy or chemotherapy for the treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
This phase I trial is combining a new drug (blinatumomab) with a commonly used immunotherapy drug (pembrolizumab) for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This phase I trial will assess how safe and tolerable a new intravenous cancer treatment is in Acute Myeloid Leukaemia, Non-Hodgkin Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukaemia patients who have not responded to prior treatment for their cancer
This phase II trial is trying to determine whether it is safer and more effective to use an oral targeted therapy alone or as a combination treatment for myelofibrosis
This phase II trial will evaluate two different doses of a targeted therapy in combination with a standard dose of azacitidine in patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome
This phase I trial is trying to find a safe and tolerable dose of a new intravenous treatment for multiple myeloma patients who have not responded to prior treatment
This phase III trial is trying to determine the best way of delivering a drug in patients who have Multiple Myeloma
This phase I/II trial is evaluating the safety and effectiveness of 5 new drugs in combination treatment for people with myelofibrosis
This phase II trial will combine two types of chemotherapy (venetoclax and cytarabine) for the treatment of acute myeloid leukaemia that has not responded or gotten worse with prior therapies
This phase II/III trial is evaluating the process of using ctDNA (tumour-derived DNA) results as a way to tailor treatment (in this case chemotherapy) in patients with stage III colon cancer
This phase I trial is trying to measure the dose of a new oral therapy (JNJ-67856633) as a possible treatment for people with B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia, who have gotten worse or not responded to other treatments
This phase III trial is comparing an experimental drug with a standard therapy for the treatment of Anaemia caused by low- to intermediate- risk Myelodysplastic Syndrome
This phase II trial is using a new oral drug (selinexor) to treat patients with Diffuse Large B-Cell Lymphoma who have no other beneficial treatment options available
This phase III trial is comparing the effectiveness of two chemotherapy drugs, given in combination with a targeted therapy in patients with advanced colorectal cancer
This Phase II/III trial is trying to determine whether a genetic test called “circulating tumour DNA” is an effective way to decide the specific type and duration of chemotherapy patients with localised pancreatic cancer should receive post-surgery
Cancer type : Pancreas
This trial is evaluating the process of using tumour-derived DNA (ctDNA) results as a way of tailoring treatment (in this case, chemotherapy) for patients with locally advanced rectal cancer
Cancer type : Rectum
This phase III trial will evaluate whether it is more or less effective to use an immunotherapy, in combination with chemotherapy, to treat women with advanced or recurrent endometrial cancer
Cancer type : Endometrium
This phase III trial is trying to determine if giving neoadjuvant, then adjuvant immunotherapy will prolong survival in patients with early stage non-small cell lung cancer
This phase III trial is combining a targeted cancer treatment and immunotherapy treatment to see how this combination impacts survival outcomes for people whose renal cell carcinoma (a type of cancer) has spread to other parts of the body
This phase I trial is trying to understand how safe and tolerable a new targeted cancer drug is for patients with B-Cell Non-Hodgkin's Lymphoma, and whether it is better given alone or in combination with another targeted cancer drug
This phase I trial is testing a new oral drug in patients with ER+, HER2- breast cancer
This phase III trial is comparing an oral drug (BGB-3111) with a combined treatment of Bendamustine and Rituximab, in patients with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This phase II trial is evaluating the combination of two anti-cancer therapies (Venetoclax and Daratumumab) and a steroid (Dexamethasone), with or without (Bortezomib) chemotherapy in patients with Multiple Myeloma
This phase III trial is evaluating an oral drug (acalabrutinib) in combination with two other drugs (bendamustine and rituximab) for the treatment of Mantle Cell Lymphoma
This phase III trial is evaluating a chemotherapy-steroid combination as maintenance therapy for transplant-eligible multiple myeloma (MM) patients who are undergoing single autologous stem cell transplantation (ASCT) as part of front-line therapy
This phase II trial is trying to find out if treatment with a targeted cancer therapy (alpelisib) and a chemotherapy (fulvestrant) increases survival compared to a chemotherapy (capecitabine) alone in men and women with ER+, HER2- breast cancer with a PIKC3A mutation
This phase III trial is evaluating the survival benefit from using concurrent chemoradiation with and without targeted therapy for the treatment of small cell lung cancer
This phase III trial is trying to determine whether adding a targeted cancer drug to hormone treatment in patients with castrate sensitive prostate cancer will result in improved survival outcomes
This phase III trial is tying to understand how safe and effective a targeted therapy is for the treatment of advanced oesophageal squamous cell carcinoma, when given in combination with chemotherapy
Cancer type : Oesophagus
This phase III trial is evaluating the safety and effectiveness of using chemo-radiotherapy with and without immunotherapy for the treatment of patients with muscle-invasive bladder cancer
Cancer type : Bladder
This phase IV trial will evaluate the safety and effectiveness of an immunotherapy, combined with chemotherapy, as first line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma
This phase III trial is trying to find the best combination of cancer drugs (SAR439859 + palbociclib, compared to letrozole + palbociclib) to improve survival in patients with ER+, HER2- advanced breast cancer who have not received prior treatment for advanced disease
This Phase II trial is trying to determine the most effective combination therapy for the immunotherapy drug Nivolumab in patients with advanced gastric cancer
This phase II/III trial is evaluating the effectiveness of a novel immunotherapy (Bintafusp Alfa) in combination with the standard of care chemotherapy (Gemcitabine and Cisplatin) to treat patients with locally advanced or metastatic Biliary Tract Cancer
Cancer type : Bile duct
This phase I/II trial is testing the safety and effectiveness of a targeted therapy in combination with chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults
Cancer type : Sarcoma
This phase I trial is trying to understand how safe and well tolerated a new targeted therapy drug is in patients with non-small cell lung cancer that has spread to other parts of the body
This phase III trial is trying to understand whether adding a form of targeted therapy to standard chemotherapy will improve overall survival for patients with malignant pleural mesothelioma
This phase III trial is comparing the safety and effectiveness of two combinations of treatment for patients who have not yet received treatment for chronic lymphocytic leaukaemia
This phase III trial is trying to understand how safe and effective an adjuvant therapy is compared to active surveillance in patients that have had their hepatocellular (liver) cancer removed or destroyed and who have a high risk of their cancer coming back
This phase II/III trial is evaluating the safety and effectiveness of adding an oral targeted therapy to a standard chemotherapy/targeted therapy combination, in patients with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer
This phase III trial is trying to understand how safe and effective it is to combine two types of immunotherapy to treat patients with non-small cell lung cancer that has spread to other parts of the body
This phase III trial is evaluating the safety and effectiveness of various targeted therapy and chemotherapy combinations for the treatment of newly diagnosed, advanced ovarian cancer
This phase II trial is evaluating how effective and well tolerated an an adjuvant immunotherapy is in patients with stage I-III Merkel Cell Carcinoma
Cancer type : Merkel cell
This phase II trial is testing a targeted therapy combination (with encorafenib and binimetinib) in patients with BRAFV600 melanoma that has spread to the brain
This phase III trial is comparing a new cancer drug with a standard form of chemotherapy for the treatment of non-small cell lung cancer
This phase II trial is evaluating a biological and chemotherapy treatment protocol (Blinatumomab + Cytarabine (AraC) and Methotrexate) for patients with Acute Lymphoblastic Leukaemia
This phase III trial will evaluate how safe and effective two types of immunotherapy are, compared to a placebo, for the treatment of locally advanced oesophageal squamous cell cancer
This phase III trial will evaluate the effectiveness of using one or two types of immunotherapy in combination with chemotherapy for the treatment of extensive-stage non-small cell lung cancer
This phase III trial is comparing the safety and effectiveness of two treatments (a targeted therapy combination versus chemotherapy) in patients with non-small cell lung cancer that has spread to other parts of the body
This phase II trial is evaluating the effect of the anti-cancer drug Rucaparib in patients with metastatic castration-resistant prostate cancer
This phase II trial is evaluating a type of immunotherapy, given on its' own or with a cancer vaccine, for the treatment of patients who have Stage II-III non-small cell lung cancer and are ctDNA positive after receiving surgery and standard care
This phase I trial is trying to understand how safe, effective and well tolerated a new oral cancer drug is, in combination with chemotherapy, for the treatment of patients with ovarian, peritoneal or fallopian tube cancer
This phase II trial is to evaluate the safety and effectiveness of using a novel immunotherapy (M7824) in conjunction with and following concomitant chemoradiation therapy (cCRT) in patients with inoperable, advanced non-small cell lung cancer.
This phase III trial is trying to determine whether treatment with a combination of targeted therapy and chemotherapy is safe and effective for patients with advanced triple negative breast cancer
This phase III trial is comparing the safety and effectiveness of two targeted therapies (monalizumab and cetuximab, compared to placebo and cetuximab) in patients with head and neck cancers that have spread to other parts of the body or have come back after treatment
This phase I trial is assessing a new targeted therapy (BI 836880 in combination with BI 754091) in patients with non-small cell lung cancer that has spread to other parts of the body and whose cancer has gotten worse on or after first line treatment
This trial is comparing the effect of having adjuvant therapy on its own, or in combination with axillary treatment, in women with early stage breast cancer
Cancer type : Multi-Cancer
This phase II/III trial is trying to understand if adding a targeted therapy to standard immunotherapy/chemotherapy treatment will improve the effectiveness of the treatment for patients with advanced head and neck cancer
This trial is trying to understand if radiotherapy could work as an effective treatment for patients with breast cancers that have had partial response to prior treatment
This phase III trial is evaluating two oral therapies (DCC-2618 and sunitinib) in patients with advanced gastrointestinal stromal tumours following prior treatment
This phase I/II trial is evaluating the safety and effectiveness of an immunotherapy combined with a type of radionuclide therapy or external beam radiation therapy in patients with Merkel Cell Carcinoma that has spread to other parts of the body
This phase III trial is looking at the safety and effectiveness of an intravenous (IV) chemotherapy drug in combination with, and compared to, other approved cancer therapies in patients with newly diagnosed, previously untreated pancreatic cancer
This phase I/II trial is trying to understand how safe a type of targeted drug therapy is in order to determine an appropriate amount to use alone or in combination with other drugs in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer
This phase III trial is evaluating the safety and effectiveness of using chemo-radiotherapy with or without immunotherapy for the treatment of patients with locally advanced cervical cancer
Cancer type : Cervix
This phase II trial is evaluating the safety and effectiveness of a new immunotherapy (zimberelimab) alone and in combination with other types of immunotherapy in patients with advanced non-small cell lung cancer
This phase II trial is assessing how safe and tolerable a new targeted therapy is when it is used in combination with immunotherapy, compared to immunotherapy alone, for the treatment of advanced non-small cell lung cancer
This phase II trial is trying to determine whether it is better to give a targeted therapy (Panitumumab) alone or in combination with standard chemotherapy (5-FU) as a primary treatment for advanced colorectal cancer
This phase I trial is trying to determine whether a new oral cancer drug is safe for patients with neuroblastoma that has not responded or has come back using previous treatment
This phase II trial is evaluating a combination of chemotherapy and immunotherapy treatments in patients with neuroblastoma that has come back or not responded to prior treatment
Cancer type : Neuroblastoma
This phase I trial is testing a cancer drug that works by switching on genes to stop cancer growth, to see if it is a suitable treatment for children whose brain cancer has not responded to, or has gotten worse on, prior treatment
This phase I/II trial is evaluating a targeted therapy to treat children and adolescents diagnosed with chronic graft versus host disease
Cancer type : Graft versus Host disease
This phase III trial is comparing two induction chemotherapy treatments in children with Acute Myeloid Leukaemia (AML)
This phase II/III trial is evaluating allogenic stem cell transplatation as an optimal therapy for children and adolescents diagnosed with Acute Lymphoblastic Leukaemia (ALL)
This phase III trial is trying to determine how well combination chemotherapy works in treating young patients with newly diagnosed B-Cell Acute Lymphoblastic Leukaemia that is likely to come back or spread
This phase II trial is evaluating a combination of hormone treatments that may be useful for pre-surgery breast cancer treatment
This phase III trial is comparing the overall survival of patients with advanced cervical cancer who receive either immunotherapy or investigator's choice of chemotherapy for the treatment of their cancer
This phase II trial is comparing alternating chemotherapy and standard of care for patients whose colorectal cancer has spread to other parts of the body
This phase III trial is comparing the safety and effectiveness of different targeted therapies for the treatment of locally advanced non-small cell lung cancer
This phase II trial is trying to determine whether adding an injection to immunotherapy is safe and effective for the treatment of advanced squamous cell carcinomas of the head and neck
This phase I/IIb trial is trying to understand whether an adjuvant immunotherapy is safe, tolerable and effective for patients who have had a stage III or stage IV melanoma removed, but are at high risk of it coming back
This phase II trial will test the safety and effectiveness of a targeted cancer drug, alone and in combination with immunotherapy, to see if it is better than standard of care chemotherapy in patients with head and neck cancers that have spread, come back and/or gotten worse after treatment
This phase III trial is trying to evaluate the safety and effectiveness of a targeted cancer drug, given alone and in combination with another targeted cancer drug or chemotherapy, for the treatment of patients with a colorectal cancer that has spread to other parts of the body
This phase III trial is comparing the effectiveness of giving immunotherapy (PD-1 inhibitors) intermittently as opposed to continuously, for the treatment of metastatic melanoma
This phase II trial is comparing the safety and effectiveness of a specialised form of radiotherapy (radioligand therapy, 177Lu-PSMA-617) given in combination with chemotherapy, versus chemotherapy alone, for patients with newly diagnosed prostate cancer
This phase II trial is comparing the effect of a chemotherapy drug (Temozolomide) alone and in combination with an immunotherapy drug (Nivolumab) for the treatment of elderly patients with a newly diagnosed glioblastoma
This trial is comparing the effectiveness of two schedules of radiotherapy for the treatment of patients with prostate cancer
This phase II trial is trying to learn how safe and effective a new immunotherapy is for the treatment of advanced cervical cancer that is unable to be removed during surgery and has gotten worse on or after chemotherapy
This phase II trial is comparing a type of targeted therapy with the investigator's choice of chemotherapy for the treatment of high-risk non-muscle invasive bladder cancer
This phase II trial is testing an oral targeted therapy (adavosertib) in patients with high grade serous ovarian cancer
Cancer type : Ovary
This phase I/II trial is trying to understand how safe and tolerable a new oral treatment is for patients with non-small cell lung cancer
This phase III trial is comparing two molecular therapies in patients with neuroendocrine tumours of stomach, intestinal or pancreatic origin
This phase I trial is assessing induction and maintenance therapy (with Avelumab and R-CHOP chemotherapy) in patients with Diffuse Large B Cell Lymphoma (DLBCL)
This phase III trial is trying to determine whether it is more or less effective to use an oral targeted therapy alone or in combination with a type of chemotherapy for the treatment of advanced non-small cell lung cancer
This phase I trial is evaluating the safety and effectiveness of an oral drug (Ipatasertib) given in combination with an immunotherapy drug (Atezolizumab) and a chemotherapy drug (either paclitaxel or nab-paclitaxel) in patients with locally advanced or metastatic triple negative breast cancer who have had no prior chemotherapy in the advanced setting
This phase I trial is evaluating the safety and recommended dose level of a new drug (intravenous JNJ-61186372) in patients with advanced non-small cell lung cancer (NSCLC)
This phase III trial is evaluating a chemotherapy combination (pemetrexed combined with carboplatin or cisplatin) with and without the drug KEYTRUDA® (pembrolizumab) for the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC)
This phase II trial is comparing the safety and effectiveness of a new, experimental treatment and standard of care in patients with acute myeloid leukaemia in complete first remission
This phase III trial trying to compare the relative survival of patients who receive either (i) nivolumab and ipilimumab (ii) nivolumab and chemotherapy or (iii) chemotherapy alone for the treatment of oesophageal and gastro-oesophageal junction cancers
This phase I trial is trying to understand how a new oral drug works and whether it is safe for the treatment of stage I-III, ER+ breast cancer that is able to be surgically removed
This phase III trial is tyring to determine whether an accerated two-week treatment of BEP chemotherapy is as effective as receiving the standrard three-week cycle, for patients with metastatic germ cell tumours
This phase II trial is trying to understand whether adding high precision radiotherapy to chemotherapy and surgery will improve treatment outcomes for patients with pancreatic cancer
This phase II trial is trying to determine the effectiveness of using focal ablative stereotactic radiosurgery (targeted radiotherapy) for the treatment of primary kidney cancer
Cancer type : Kidney
This phase III trial is examining personalised radiation therapy for low-risk early breast cancer
This phase III trial is trying to understand the effectiveness of a hormone therapy in men requiring radiation therapy for localised prostate cancer that has a high risk of coming back after treatment
This phase I/II trial is trying to understand whether alternating between two targeted therapies will improve treatment outcomes for patients with ALK-rearranged non-small cell lung cancer
This phase III trial is comparing an immunotherapy to standard of care treatment in adults who have been diagnosed with B-cell Non-Hodgkin Lymphoma and have failed prior immunochemotherapy
This phase II trial is comparing molecular-guided therapy with standard platinum-containing chemotherapy for the treatment of advanced cancers of the unknown primary (CUP)
Cancer type : Cancer of Unknown Primary
This trial is trying to determine how effective adjuvant fractionated radiotherapy is, in treating newly diagnosed atypical meningioma, in comparison to active monitoring
This phase II trial is trying to determine how effective a new biological therapy (RO7198457) and immunotherapy combination is, compared to immunotherapy on its own, in the treatment of advanced melanoma
This phase I trial is evaluating the safety of an oral drug (GDC-9545) when it is given alone or in combination with other therapies (Palbociclib and/or LHRH Agonist) in patients with a ER+ breast cancer that has spread to other parts of the body
This phase I trial is evaluating an oral drug (N-methyl-pyrrolidone) in patients with relapsed Myeloma
This phase III trial is evaluating pembrolizumab (an immunotherapy drug) as a treatment for patients with Hodgkin Lymphoma
Cancer type : Hodgkin's Disease (Hodgkin's Lymphoma)
This phase II trial is combining a targetted therapy (ibrutinib) with a chemotherapy drug (venetoclax) for the treatment of Chronic Lymphocytic Leukaemia and Small Lymphocytic Leukaemia
This phase III trial is trying to understand how safe and effective it is to use targeted therapy, immunotherapy and chemotherapy (given directly into the blood vessel) for the treatment of hepatocellular (liver) cancer that has not spread to other parts of the body
This phase I trial is trying to understand how much immunotherapy is safe and effective for the treatment of castration-resistant prostate cancer that has spread to other parts of the body
This phase II trial is trying to understand the safety and potential impact of adding radiotherapy to standard hormone therapy in patients with castration resistant prostate cancer that has not previously been treated using chemotherapy and has spread to other parts of the body
This phase II trial is evaluating the addition of an immunotherapy drug following long-course chemo-radiotherapy in patients with a locally advanced rectal cancer that is able to be surgically removed
This phase III trial is evaluating the safety and effectiveness of two targeted therapies, compared to chemotherapy, for the treatment of non-small cell lung cancer that has spread to other parts of the body and has gotten worse on prior treatment
This phase III trial will evaluate the safety and effectiveness of an immunotherapy (nivolumab), given in combination with a chemotherapy (docetaxel), in men with advanced castration-resistant prostate cancer that has gotten worse after second-generation hormone therapy
This phase III trial is trying to understand the safety and effectiveness of using an immunotherapy (pembrolizumab) and hormone therapy (Enzalutamide plus androgen deprivation therapy) to treat patients with metastatic hormone sensitive prostate cancer (mHSPC)
This phase II trial is trying to determine how safe and tolerable the biological therapy, AK104, is for the treatment of patients who have cervical cancer that has spread or come back following prior treatment
This Phase II trial is evaluating an intratumoral therapy (within a tumor) and electroporation (a microbiology technique that applies an electric field to cells in the body) in combination with an immunotherapy agent (Pembrolizumab) in patients with advanced stage II/IV melanoma
This phase II trial is evaluating the combination of nivolumab (an immunotherapy drug) and two other drugs (BNC105 or BBI608) in patients with colorectal cancers that have spread to other parts of the body and have failed prior therapies
This phase III trial is evaluating the safety and effectiveness of an immunotherapy (Nivolumab) in combination with a chemotherapy drug (Paclitaxel) in patients with ER+/HER2- breast cancer
This phase III trial is comparing pre- and post- surgical immunotherapy (Nivolumab alone or in combination with NKTR-214) with standard of care therapy in patients with muscle invasive bladder cancer who are unable to have a certain type of chemotherapy (Cisplatin)
This phase III study is evaluating the benefits of combining targeted therapies (Nivolumab and/or BMS-986205) with chemotherapy for treatment before surgery (radical cystectomy), followed by continued treatment with the targeted therapy post surgery for patients with Muscle-Invasive Bladder Cancer
This phase IV trial is trying to understand if infusion of intravenous iron results in improved physical fitness of patients undergoing surgery for colorectal cancer
This phase IV trial is trying to determine if giving an iron infusion to iron-deficient colorectal cancer patients who are anaemic versus not anaemic will improve their physical fitness for planned surgery
This phase I trial is trying to determine whether it is safe to give the drug Nivolumab before and in combination with the drug Rituximab, in patients who have previously untreated Follicular Lymphoma
This phase I trial is combining a new drug (SBP-101, delivered as an injection) with two chemotherapy drugs (nab-paclitaxel and Gemcitabine) in patients with previously untreated pancreatic cancers that have spread to other parts of the body
This phase I/II trial will use functional imaging (such as a PET scan) to evaluate the treatment response of non-small cell lung cancer patients receiving an immunotherapy drug (M7824) compared to non-small lung cancer patients receiving standard of care chemotherapy
This phase II trial is trying to determine how effective a targeted therapy is in the neoadjuvant (pre-) treatment of cutaneous squamous cell carcinoma
Cancer type : Cutaneous Squamous Cell Carcinoma (CSCC)
This phase III trial is trying determine whether the targeted therapy (Selpercatinib) is safe and more effective than current standard targeted therapies (Cabozantinib or Vandetanib) in patients with advanced thyroid cancer
This phase II trial is testing a new biological therapy (V937, given as an injection or into the vein, in combination with immunotherapy) and comparing it with standard immunotherapy alone, in patients with advanced melanoma
This phase III trial is comparing the effectiveness between using a targeted therapy (Palbociclib) in conjunction with endocrine therapy and endocrine therapy alone to treat patients with HR+, HER2 negative breast cancer
This phase III trial is comparing a new oral therapy (Selpercatinib) with a standard treatment in patients with advanced non-small cell lung cancer
This phase III trial is trying to determine whether it is better to give a type of immunotherapy (Pembrolizumab) alone or in combination with an oral drug (Lenvatinib) in people with urothelial cancers that have spread to other parts of the body
This phase III trial is trying to determine whether a chemotherapy drug (Cyclophosphamide) is better than the current standard of care at preventing graft versus host disease in patients that have recently received a bone marrow transplant
This phase Ib/III trial is examining the effectiveness and safety of using a novel targeted therapy (Ipatasertib) in combination with another targeted therapy (Palbociclib) and chemotherapy (Fulvestrant) to treat advanced unresectable or metastatic breast cancer
This phase II trial is evaluating the use of two targeted therapies (Capmatinib and Pembrolizumab) in comparison to one targeted therapy (Pembrolizumab) to treat locally advanced or metastatic non-small cell lung cancer
This is a phase III trial evaluating the effectiveness of targeted therapy (Pembrolizumab) plus chemotherapy (Gemcitabine/Cisplatin) to treat advanced or unresectable biliary tract carcinoma
This phase II trial is evaluating the effectiveness of using two targeted therapies (ipilimumab and nivolumab) in combination with intracranial stereotactic radiotherapy to treat melanoma brain metastases
Cancer type : Brain
This phase III trial is trying to determine whether it is more effective to use radiotherapy alone or in combination with immunotherapy in patients will non-small cell lung cancer
This phase II trial is assessing the benefits of using a targeted therapy (cemiplimab) in combination with a biological therapy (RP1) to treat patients with advanced or metastatic cutaneous squamous cell carcinoma
This phase II trial is evaluating the safety and effectiveness of two immunotherapy drugs (durvalumab and tremelimumab) when given with chemotherapy for the treatment of EGFR mutant non-squamous non-small cell lung cancer (NSCLC)
This phase II trial is evaluating the effectiveness of using a targeted therapy (Pamiparib) to treat patients with high grade serous ovarian cancer or carcinosarcoma
This phase III trial is evaluating a type of bladder surgery alone and in combination with immunotherapy (Pembrolizumab) in patients with muscle-invasive bladder cancer
This phase III trial is comparing an immunotherapy (Pembrolizumab) and a targeted therapy (Levatinib) with chemotherapy in patients with stage III or IV endometrial cancer, or in patients whose cancer has come back following prior treatment
This phase 1b trial is evaluating the effectiveness of combining three targeted therapies (palbociclib, letrozole and venetoclax) to treat patients with ER and BCL-2 positive locally advanced or metastatic breast cancer
This phase III trial is comparing two chemotherapy combinations for the treatment of advanced biliary tract cancer
This phase III trial is evaluating the safety and effectiveness of two oral drugs (abiraterone alone and in combination with olaparib) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior chemotherapy or new hormonal therapies
This phase III trial is comparing outcomes for patients with Non-Small Cell (NSC) Lung Cancer, who are receiving second- or third- line chemotherapy with docetaxel alone and in combination with plinabulin, for advanced stage or metastatic disease
This phase 2 trial is evaluating the effectiveness of using an immunotherapy (talimogene laherparepvec) in combination with a targeted therapy (pembrolizumab) to treat patients with melanoma, who have had disease progression while on immune checkpoint inhibitors (anti-PD-1 therapy)
This phase III trial is evaluating E7777 as an intravenous treatment for patients with persistant and recurrent Cutaneous T-cell Lymphoma
This is a phase II trial evaluating the effectiveness of targeted therapy (Pamiparib) for the treatment of patients with recurrent High Grade Serous Ovarian Cancer or carinosarcoma
This phase III trial is comparing maintenance therapy with two oral drugs (Olaparib and Cediranib), versus Olaparib as a maintenance therapy alone, in patients with relapsed ovarian cancer
This phase III trial is comparing the safety and effectiveness of an immunotherapy drug (Atezolizumab) and a chemotherapy drug (Paclitaxel), given in combination with the investigator's choice of standard chemotherapy, for the treatment of stage II or stage III triple negative breast cancer (TNBC)
This phase 3 trial is comparing the effectiveness of concurrent chemoradiotherapy (CCRT) followed by different combinations targeted therapies (nivolumab, ipilimumab or durvalumab) for the treatment of locally advanced non-small call lung cancer
This phase III trial is assessing the safety and effectiveness of combining treatment with an oral targeted cancer drug (olaparib) and a type of immunotherapy (pembrolizumab) in patients with castrate-resistant prostate cancer that has spread to other parts of the body and not responded to prior treatments
This phase III trial is evaluating an oral prostate cancer treatment (Apalutamide) in patients with high risk, localised or locally advanced prostate cancer who are eligible for surgery
This phase II trial is testing an oral anti-cancer therapy (Brigatinib) in patients who have ALK+ non-small cell lung cancer
This phase 2 trial is assessing the clinical benefit of adding a statin (Simvastatin) to standard chemotherapy and radiotherapy to treat patients with rectal cancer before surgery
This phase II trial is evaluating an immunotherapy (zolbetuximab) in combination with chemotherapy (gemcitabine and nab-paclitaxel) in patients who have pancreatic cancer that has spread to other parts of the body
This phase 3 trial is comparing the effectiveness of using two targeted therapies (Pembrolizumab and Olaparib) for the first line treatment of metastatic Squamous Non-small Cell Lung Cancer
This phase 3 trial is comparing the effectiveness of using either two targeted therapies (pembrolizumab and olaparib), or one targeted therapy (pembrolizumab) with a chemotherapy (pemetrexed) for the treatment of metastatic Non-Small-Cell Lung Cancer
Cancer type : Mesothelioma
This phase 3 trial is evaluating the safety and effectiveness of using a novel gene therapy (rAd-IFN) in combination with an anti-inflammatory drug (Celecoxib) and chemotherapy (Gemcitabine) for the treatment of patients with pleural Mesothelioma
This phase 3 trial is comparing the benefit of using targeted therapies, either in combination (Nivolumab plus Ipilimumab) or alone (nivolumab) to treat patients with metastatic colorectal cancer.
This phase 3 study is evaluating the effectiveness and safety of a targeted therapy (Infigratinib) in comparison with the standard of care chemotherapy (Gemcitabine plus Cisplatin) for treatment of patients with inoperable or metastatic cholangiocarcinoma
This Phase III trial is comparing the effects of giving an oral drug (Osimertinib) alone and in combination with stereotactic radiosurgery (SRS) in patients with non-small cell lung cancer (NSCLC) that has spread to the brain
This is a phase II trial evaluating the effectiveness of using targeted therapies, either alone (Ipilimumab) or in combination (Ipilimumab and Nivolumab), in comparison with chemotherapy (Cabazitaxel) to treat patients with metastatic castration-resistant prostate cancer who have progressed after previous chemotherapy treatment with Docetaxel
This phase I trial is testing the safety and activity of two immunotherapies (RO6874281 and Pembrolizumab) in patients with advanced Melanoma that has spread to other parts of the body
This phase II trial is trying to find out how effective it is to treat patients, diagnosed with T-Cell Prolymphocytic Leukemia, with a targeted therapy (Ibrutinib) in combination with chemotherapy (Venetoclax)
Cancer type : Leukaemia
This phase II trial is evaluating a new oral drug (CB-839) in combination with cabozantinib (a different oral drug), compared to cabozantinib alone in patients with advanced or metastatic renal cell carcinoma
This phase 3 trial is comparing the benefits of combining two targeted therapies (Talazoparib and enzalutamide) in comparison to using enalutamide alone for the treatment of patients with metastatic castration-resistant prostate cancer
This phase I/II trial is evaluating the effectiveness and safety of a new targeted therapy (DZD9008) to treat advanced recurrent Non-small Cell Lung Cancer with EGFR or HER2 mutations
This phase II trial is evaluating the safety and effectiveness of using a targeted therapy (TTAC-0001) to treat patients with recurrent glioblastoma which progressed on therapy that included Bevacizumab
Cancer type : Glioblastoma (GBM)
This phase III trial evaluates the effectiveness and safety of using a targeted therapy (Durvalumab), either alone or in combination with another targeted therapy (Bevacizumab), to extend remission in patients who have a high risk of hepatocellular carcinoma recurrence post curative treatment
This phase 1b/2 trial is evaluating the effectiveness of two targeted therapies (venetoclax and obinutuzumab) in combination with an immunotherapy (lenaliomide) to treat follicular lymphoma
This phase III trial is trying to determine if extended post-radiation chemotherapy will improve survival outcomes in patients with newly diagnosed glioblastoma
This phase II trial is evaluating 3 different drug combinations for advanced melanoma treatment and prevention of recurrence
This phase III trial is trying to determine how well an investigational drug (NKTR-214) works when combined with an immunotherapy drug (Nivolumab) for the treatment of previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread
This phase III trial is evaluating a new oral drug (DCC-2618) for the treatment of advanced gastrointestinal stromal tumours that have previously been treated
This trial is evaluating safety and effectiveness of a new targeted therapy (HMPL-523) to treat patients with recurrent lymphoma
This phase III trial is evaluating the effectiveness of administering a targeted therapy (Pembrolizumab) in combination with chemotherapy drugs (Gemcitabine and Cisplantin) before surgery to treat patients with bladder cancer
This phase III trial is trying to determine whether an immunotherapy drug (Pembrolizumab) is an effective therapy to give after surgery and radiation in patients with locally advanced cutaneous squamous cell carcinoma
This phase III trial is evaluating the safety and effectiveness of the immunotherapy drug, Pembrolizumab, in patients with surgically removed high-risk stage II melanoma
This phase I trial evaluates the safety and effectiveness of engineered CAR-T cells (CD19 targeted) alone for treatment of patients with diffuse large B-cell lymphoma and in combination with targeted therapy (ibrutinib) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
This phase III trial is trying to determine how effective an oral therapy (niraparib) is in combination with a hormone therapy and a steroid (abiraterone acetate and prednisone, AA-P) in patients with metastatic prostate cancer
This phase III trial is comparing the addition of an investigational drug (polatuzumab vedotin) to R-CHP and R-CHOP chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
This study evaluates the effectiveness of using a combination of therapies (Daratumumab-lenalidomide-dexamethasone) with stem cell transplant to treat patients diagnosed with Multiple Myeloma who have not responded to standard treatment
This phase II trial is trying to determine if treatment with an immunotherapy (durvalumab) is beneficial for patients who have recurrent ovarian cancer
This phase III trial is trying to determine the effectiveness of an immunotherapy drug (pembrolizumab), compared to the placebo, in combination with chemotherapy for the treatment of HER2 negative gastric (stomach) cancer
This phase III trial is trying to determine how safe and effective an immunotherapy drug (pembrolizumab) is, when it is given alone and in combination with an oral drug (lenvatinib), as a first line treatment for patients with advanced melanoma
This phase III trial is evaluating neoadjuvant treatment with atezolizumab and a type of chemotherapy in patients with Stage II, IIIA, or select IIIB non−small cell (NSC) lung cancer that is able to be surgically removed
This Phase III trial is evaluating an immunotherapy agent (Pembrolizumab) as a monotherapy for patients who have Renal Cell Carcinoma and have undergone a nephrectomy surgical procedure
This phase II trial is evaluating the safety and effectiveness of an immunotherapy (Pembrolizumab) in patients with high risk, non-muscle invasive bladder cancer, who have not responded to prior therapy
This phase III trial is comparing three drugs (Lenvatinib in combination with Everolimus or Pembrolizumab) with another targeted drug (Sunitinib) as a first-line treatment for patients with advanced Renal Cell Carcinoma
This is a phase I trial assessing the safety and tolerability of using immunotherapy drugs (PDR001 and /or MBG453) in combination with chemotherapy (Decitabine) to treat patients with Acute Myleoid Leukaemia or High Risk Myelodysplastic Syndrome
This phase II trial is evaluating oral dosing of the drug dasatinib in elderly patients with Chronic Myelogenous Leukaemia (CML)
Cancer type : Chronic Myelogenous Leukaemia
This Phase II trial is evaluating the drug pembrolizumab (commonly used in immunotherapy) as a treatment for patients with newly diagnosed Hodkgin Lymphoma
This phase III trial is trying to determine whether adding venetoclax (an oral drug) to azacitidine treatment works better than azacitidine treatment on its own in patients with newly diagnosed Acute Myeloid Leukaemia (AML)
This phase I trial is evaluating the combination of an oral therapy (olaparib) and a combination therapy (177Lu-PSMA) in patients with castration resistant prostate cancer that has spread to other parts of the body and progressed on other targeted treatments
This phase II trial is evaluating an oral systemic therapy in patients with HRAS positive Head and Neck Squamous Cell Carcinoma
This phase I/II trial is evaluating two immunotherapy drugs (MEDI9447 and durvalumab) given alone or in combination, with chemotherapy, in patients with pancreatic cancer that has spread to other parts of the body
This phase II/III trial is testing a new drug (ADI-PEG 20) in combination with standard chemotherapy for patients with pleural mesothelioma
This phase II/III trial is comparing preoperative chemradiotherapy with preoperative chemotherapy for patients with resectable gastric cancer
This phase III trial is testing an oral chemotherapy drug (ixazomib) as a maintenance therapy for patients with newly diagnosed Multiple Myeloma
This phase I/II trial is evaluating the addition of a new treatment (Denosumab) to standard immunotherapies for patients with metastatic melanoma
This phase II trial is assessing 6 cycles of chemotherapy in patients with Diffuse Large B-Cell Lymphoma
Cancer type : Diffuse Large Cell Lymphoma
This phase II/III trial is combining bendamustine (a chemotherapy drug) with either MOR208 or rituximab (two types of antibody therapy) for the treatment of Diffuse Large B-cell Lymphoma
This phase III trial is testing a drug called BBI-608 in combination with other drugs, for patients with previously treated metastatic colorectal cancer (CRC)
This phase I/II trial is trying measure the dose of a new oral therapy (LOXO-305) as a treatment for people with Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Leukaemia (SLL) or B-Cell Non-Hodgkin Lymphoma who have failed or unable to receive standard of care
This phase II trial is using an oral drug (Cabozantinib) to treat patients with locally advanced or metastatic clear cell renal cell carcinoma who have previously received or are unable to receive immunotherapy
This phase III trial is comparing two drugs (BGB-3111 and ibrutinib) in the treatment of Waldenström's Macroglobulinemia (a type of Non Hodgkin Lymphoma)
This phase III trial is trying to determine whether the combination of an immunotherapy (Durvalumab) and a standard of care therapy (Bacillus Calmette-Guerin) is better than giving standard of care therapy alone, in the treatment of non-muscle-invasive bladder cancer
This phase III trial is assessing a first line treatment combining immunotherapy and chemotherapy, versus chemotherapy alone, in patients with locally advanced or metastatic urothelial cancer
This phase II trial is evaluating a biological therapy (Tavokinogene Telseplasmid - delivered by electroporation), in combination with an immunotherapy drug (Pembrolizumab), in patients with advanced triple negative breast cancer
This phase II trial is evaluating the most effective dose of an oral study drug (lenvatinib) in patients being treated for Thyroid Cancer
Cancer type : Thyroid
This phase II trial is evaluating a new form of immunotherapy (xentuzumab) to see whether it enhances combination treatment with a chemotherapy drug (Everolimus) and hormone therapy drug (Exemestane) in patients with hormone receptor positive (HR+), HER2- breast cancer that has spread to other parts of the body
This phase III trial is evaluating an oral drug (Erdafitinib) for the treatment of advanced urothelial cancer, compared to standard treatment with chemotherapy or immunotherapy agents
This trial is testing hormone therapy, using oral (Z)-Endoxifen, as a treatment for patients with invasive breast cancer
This phase III trial is evaluating a treatment for anaemia in patients with lower risk Myelodysplastic Syndrome (MDS) and low red blood cell (RBC) transfusion burden (LTB)
This phase II trial is combining the drug Carfilzomib with an immunotherapy agent (Thalidomide) and a steroid (Dexamethasone) in patients with relapsed or refractory Multiple Myeloma
This phase II trial is evaluating whether chemotherapy (cyclophosphamide) post-stem cell infusion will prevent Graft versus Host disease in blood cancer patients requiring a haplo-identical stem cell transplant
This phase II trial is evaluating the combination of three immunotherapy drugs (Atezolizumab, Bevacizumab and Cobimetinib) in patients diagnosed with High Grade Serous Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer
This phase I trial is evaluating the safety and recommended dose of an oral therapy (Lenalidomide) in patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome at high risk of relapse
This phase II trial is testing the safety of an immunotherapy treatment in infants with newly diagnosed Acute Lymphoblastic Leukaemia (ALL)
This phase II trial is investigating the activity of two oral drugs (dabrafenib and trametinib) in children and adolescents who have BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma
This phase II trial is testing three oral drugs (Erlotinib, Everolimus and Dasatinib) as a possible treatment for Diffuse Intrinsic Pontine Glioma (DIPG)
Cancer type : Glioma
This phase II trial is trying to determine the benefit of adding Bevacizumab (an intravenous drug) to chemotherapy treatment with Vinblastine, in children and adolescents with low grade gliomas
This phase I/II trial is using an oral drug (LOXO-101) as a treatment in children and adolescents with central nervous system tumours
Cancer type : Central Nervous System
This phase III trial is comparing surgery and radiation therapy in the treatment of stage I Non-Small Cell (NSC) Lung Cancer
This phase I/II trial is evaluating two biological therapies (Nivolumab alone and in combination with Ipilimumab) in children and adolescents that have been diagnosed with advanced Central Nervous System (CNS) cancers
This phase III trial is evaluating treatment options for children and adolescents with standard risk of first relapsed Acute Lymphoblastic Leukemia (ALL)
This phase I/II trial is combining an oral drug (ponatinib) with 5- azacitidine for the treatment of Acute Myeloid Leukaemia (AML)
This phase II/III trial is comparing four widely used chemotherapy regimens for patients with primary refractory and recurrent Ewing Sarcoma
This Phase II trial is comparing the effectiveness of a chemotherapy drug (Olaparib) alone and as part of a combination therapy in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers that have homologous recombination repair defects
This phase III trial is evaluating the safety and effectiveness of adding an immunotherapy (Pembrolizumab) to a combination treatment with another immunotherapy (Trastuzumab) and standard of care (SOC) chemotherapy in patients with HER2 positive stomach cancers
This phase II trial is evaluating different combinations of therapies in patients with advanced renal cell carcinoma
This phase II trial is trying to determine whether combining an anti-HER2 therapy (trastuzumab) with two immunotherapy drugs (durvalumab and tremelimumab) will improve clinical outcomes for patients that are diagnosed with advanced HER2+ breast cancer
This phase II/III trial is evaluating the safety and effectiveness of a new oral drug (TGR-1202) in combination with a type of immunotherapy (ublituximab) with or without chemotherapy (bendamustine) in patients with recurrent or refractory Non-Hodgkin's Lymphoma
This phase I trial is evaluating the safety and dose of an investigational immunotherapy drug (AMG 160) in patients with metastatic castration resistant prostate cancer
This phase II trial is evaluating radiotherapy and immunotherapy for the treatment of advanced triple negative breast cancer (TNBC)
This phase II trial is evaluating the effectiveness of an anti-cancer drug (veliparib), radiotherapy and adjuvant (temozolomide) chemotherapy in patients with newly diagnosed Glioblastoma (GBM)
This phase III trial is assessing the addition of andecaliximab to a combination chemotherapy as a first line treatment for people with advanced gastric or gastro-oesophageal cancers
This phase III trial is looking at the effect of adding mitomycin C (a chemotherapy drug) to standard treatment, in patients with invasive bladder cancer
This phase III trial is evaluating the addition of the drug Isatuximab (SAR650984) to chemotherapy treatment (with Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone) in newly diagnosed patients with Multiple Myeloma
This phase III trial is trying to determine the benefit of adding an immunotherapy drug (Ibrutinib) to Rituximab treatment in patients who have been diagnosed with Follicular Lymphoma and not yet received treatment
This phase III trial is comparing an oral drug (Alectnib) and platinum based chemotherapy for the treatment of ALK+ Non-Small Cell (NSC) Lung Cancer
This phase I/II trial is evaluating combinations of different immunotherapy-based treatments in patients with metastatic non-small cell (NSC) lung cancer
This Phase Ib trial is evaluating the safety and effect of giving pembrolizumab (commonly used as an immunotherapy drug), to patients with metastatic non-small cell (NSC) lung cancer, before or after radiotherapy treatment
This phase I trial is combining a new intravenous drug (RO7082859) with an immunotherapy (Rituximab or Obinutuzumab) and chemotherapy (CHOP) treatment in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This phase III trial is evaluating an immunotherapy (tabelecleucel) for the treatment of Epstein-Barr Virus-associated post-transplant lymphoproliferative disease in the setting of solid organ transplant after failure of rituximab or rituximab plus chemotherapy
Cancer type : Lymphoma
This phase III trial is evaluating the addition of an immunotherapy drug (Avelumab) to standard chemoradiation as a first line treatment for locally advanced cancers of the head and neck
This phase III trial is comparing two drugs (Rovalpituzumab Tesirine and Topotecan) in patients with advanced or metastatic Small Cell Lung Cancer (SCLC) that has gotten worse following front-line chemotherapy
Cancer type : Small Cell Lung Cancer
This phase III trial is assessing the safety and efficacy of nivolumab (a chemotherapy drug) in treating patients who have had surgery for urothelial cancer
This phase III trial is evaluating an investigational drug (Sutimlimab) in patients with Primary Cold Agglutinin disease, who have recently received a blood transfusion
This phase III trial is comparing treatment with an intravenous drug (Zolbetuximab) and chemotherapy (mFOLFOX6), versus chemotherapy alone, in patients with CLDN, HER2- advanced or metastatic gastric or gastroesophageal junction cancer
This phase III trial is trying to show the benefit of adding a chemotherapy drug (palbociclib) to anti-HER2 therapy plus endocrine therapy in the treatment of HER 2+ breast cancer that has spread to other parts of the body
This phase II trial is evaluating a targeted cancer drug (Panitumumab) as a second line therapy for patients with advanced pancreatic ductal adenocarcinoma with wild-type KRAS mutation
This phase III trial is investigating asprin for Dukes C and high risk Dukes B colorectal cancers
This phase I trial is assessing simultaneous radiotherapy and immunotherapy (with durvalumab) in patients with relapsed Diffuse Large B Cell Lymphoma
This phase I trial is evaluating the combination of two drugs (Brentuximab vedotin and lenalidomide) for the treatment of relapsed/refractory T-cell lymphoma or Hodgkin Lymphoma
This phase I trial is assessing the safety of administering a drug (pembrolizumab) by injection beneath the skin for the treatment of advanced melanoma
This phase II trial is testing a drug (pembrolizumab) in combination with chemotherapy and radiotherapy for the treatment of locally advanced Stage III non-small cell lung cancer that cannot be removed by surgery
This phase I trial is testing a new drug (KB004) in patients with recurrent glioblastoma
This phase III trial is comparing a high dose of palliative radiotherapy alone and in combination with concurrent chemotherapy in patients with metastatic Non-Small Cell (NSC) Lung Cancer
This phase III trial is comparing the drug, avelumab, with platinum-based doublet chemotherapy in Non-Small Cell (NSC) Lung Cancer patients with PD-L1+ tumours
This phase II trial is evaluating a new drug (guadecitabine) in patients with T-Cell Lymphoma
This phase III trial is comparing Brentuximab Vedotin and CHP chemotherapy, with standard chemotherapy, for the treatment of mature T-Cell Lymphoma
This phase II trial is evaluating a targeted radiotherapy in men with an advanced prostate cancer that has spread to other parts of the body and is not responding to systemic treatment
This phase III trial is evaluating an oral drug (Relugolix) in the treatment of advanced prostate cancer
This phase III trial is comparing an oral drug (Rucaparib) with standard treatment in patients who have metastatic castration-resistant prostate cancer
This trial is assessing the safety and efficacy of Irreversible Electroporation for the removal of prostate cancer
This phase III trial is comparing pembrolizumab (an immunotherapy agent) with standard therapy for patients with advanced oesophageal and gastro-oesophageal junction cancers that have gotten worse after first line treatment
This phase II/III trial is comparing two oral drugs (ixazomib and pomalidomide) both given in combination with a steroid (dexamethasone) in the treatment of Multiple Myeloma
This phase I trial is trying to determine whether it is better to give a new drug (RO6870810) alone or in combination with a different anti-cancer drug (daratumumab) when treating patients with advanced Multiple Myeloma
This phase III trial is comparing the effectiveness of an immunotherapy drug (Ipilimumab) with and without an injection of IMO-2125 within the tumour of patients who have advanced melanoma that has gotten worse on prior immunotherapy treatment
This phase I trial is trying to determine the recommended dose of a new drug (IMP321) when given in combination with an immunotherapy agent (pembrolizumab) for people with metastatic melanoma
This phase II trial will assess the effectiveness of different Medullablastoma treatments in patients, according to their clinical risk and molecular subtype
Cancer type : Medullablastoma
This phase II/III trial is looking at different treatment protocols for children and adolescents with Langerhans Cell Histiocytosis
Cancer type : Langerhans Cell Histiocytosis
This phase III trial is evaluating chemotherapy intensification in Hodgkin Lymphoma patients who receive less radiotherapy
This phase II trial is evaluating ABT414 alone and in combination with chemotherapy for patients with recurrent glioblastoma
This phase III trial is evaluating the drug rituximab, alone and in combination with copanlisib (another drug), for the treatment of Non Hodgkin Lymphoma
This phase II trial is evaluating the combination of revlimid (chemotherapy) and rituximab maintenance therapy in the treatment of patients with Follicular Lymphoma
This phase II trial is evaluating an intravenous drug (prexasertib) in women with platinum-resistant or refractory recurrent ovarian cancer
This phase III trial is comparing post-radiation chemotherapy and observation for the treatment of young people with newly diagnosed ependymomas
Cancer type : Ependymomas
This phase II trial is evaluating an intravenous drug (Vinorelbine) for the treatment of recurrent C5 high grade serous, endometrioid, or undifferentiated primary peritoneum, fallopian tube or ovarian cancer
This phase II trial is trying to determine whether the use of mirena, metformin or a weight loss intervention is effective in the treatment of early-stage endometrial cancer
This phase I trial is combining pembrolizumab (an immunotherapy drug) and dinaciclib (an investigational agent) for the treatment of Multiple Myeloma, Diffuse Large Cell Lymphoma and Chronic Lymphocytic Leukaemia
This phase II trial is evaluating an oral chemotherapy drug (Venetoclax) in participants with Chronic Lymphocytic Leukaemia (CLL)
Cancer type : Chronic Lymphocytic Leukaemia
This phase III trial is evaluating two drugs (acalabrutinib and ibrutinib) for the treatment of patients who have been diagnosed Chronic Lymphocytic Leukemia (CLL)
This phase III trial is evaluating acalabrutinib and rituximab (two anti-cancer drugs), given in combination with idelalisib or bendamustine (chemotherapy), for the treatment of Chronic Lymphocytic Leukaemia (CLL)
This phase I/II trial is evaluating various immunotherapy based treatment combinations as a way of treating patients with a Triple Negative Breast Cancer (TNBC) that has spread to other parts of the body
This phase III trial is assessing the safety and effectiveness of neoadjuvant chemotherapy, with docetaxel and anthracycline, in patients with advanced breast cancer
This phase II study is assessing the safety and feasibility of combining pembrolizumab (an immunotherapy agent) with chemoradiotherapy in the treatment of bladder cancer
This phase II trial is evaluating the effectiveness of an intravenous drug (Blinatumomab) in treating patients with High-risk Diffuse Large B-cell Lymphoma following an autologous Hematopoietic Stem-cell Transplantation
This phase I trial is investigating a new drug (BGB3111) for the treatment of B-Cell Lymphomas
This phase II trial is comparing an oral antbiotic treatment with an intravenous treatment for patients with blood cancer who have low levels of antibodies in their blood (hypogammaglobulinemia)
This phase III trial is evaluating tretinoin and arsenic trioxide for the treatment of patients with newly diagnosed Acute Promyelocytic Leukemia
Cancer type : Acute Promyelocytic Leukaemia
This phase III trial is assessing the relapse-free survival of patients who are in complete first remission for Acute Myeliod Leukaemia (AML) and who are randomised to receive gilteritinib after they have completed two years of induction chemotherapy
This phase I trial is testing a new oral drug (MAX-40279) for the treatment of Acute Myelogenous Leukaemia (AML)
This trial is studying how well different therapies work in treating infants with newly diagnosed acute leukemia
Cancer type : Acute Lymphoblastic Lymphoma
This phase I trial is evaluating an intravenously administered drug (CX-5461) for the treatment of advanced blood cancer
This phase I/II trial is trying to determine how much carfilzomib (an anti-cancer drug) should be used, alone and in combination with induction chemotherapy, to treat children with Acute Lymphoblastic Leukaemia (ALL)
This phase III trial is trying to determine whether blinatumomab (a drug) is better as a consolidation therapy than standard chemotherapy for patients with Acute Lymphoblastic Leukaemia (ALL)
This phase I trial is testing different doses (amounts) of a new targeted therapy in adults with HER2-positive cancer
This phase I trial is trying to find the best dose of a chemotherapy in patients with advanced solid cancers (excluding some types of blood cancer)
This phase I trial is trying to determine how safe and effective CBT-501 is in individuals with an advanced solid cancer (excluding blood cancer) that has got worse or come back
This phase II trial has been designed to evaluate the safety and effectiveness of using targeted therapies or immunotherapy as a single agent or combination treatment in patients with advanced solid tumours that have specific genetic alteration(s)
This phase I/II trial will begin to understand how safe and tolerable a new cancer drug (D-1553) is as a monotherapy and combination treatment for people with advanced solid cancers that have a KRasG12C mutation
This phase I trial will begin to understand how safe and tolerable a combination therapy (containing a new cancer drug, IMP4297, and a type of chemotherapy) is in people diagnosed with advanced solid cancer, including small cell lung cancer
This Phase II trial is evaluating an oral drug (Olaparib) in the treatment of HR-deficient metastatic breast cancer and relapsed ovarian cancer without BRCA1 and BRCA2 mutations
This phase I/II trial is evaluating the safety and effectiveness of an oral drug (BMS-813160) alone or in combination with immunotherapy (Nivolumab) and/or chemotherapy in patients with advanced solid cancers, particularly colorectal cancer or pancreatic cancer
This phase I trial is evaluating the combination of two immunotherapy drugs (AB928 and AB122) in patients with certain types of advanced cancer
This phase I trial is evaluating the safety of a drug (FN-1501) in patients with advanced solid tumours
This phase II trial is trying to determine how safe and tolerable a targeted therapy is for the treatment of several different cancer types
This Phase II trial is trying to determine how safe and effective a combination therapy (with pembrolizumab and lenvatinib) is in treating patients with select advanced cancers
This phase I trial is assessing the combination of a new intravenous drug (PG545) and an immunotherapy drug (Nivolumab) in patients with advanced solid cancers, as well as patients with metastatic pancreatic cancer
This phase I trial is evaluating the safety and tolerability of a novel immunotherapy (HBM4003) in patients with advanced solid tumours
This phase I/II trial will begin to understand how safe and tolerable a new type of targeted therapy is for patients with advanced solid cancers, given as a monotherapy (alone) or in combination with another targeted cancer therapy
This phase I/II trial is trying to understand how safe and well tolerated a new immunotherapy is when combined with a standard immunotherapy drug in patients with advanced cancer
This phase I trial will assess how safe and well tolerated a new cancer drug is on its' own or following pre-treatment in patients with TYRP1-positive melanomas who have progressed on (or are not eligible for) standard of care
Cancer type : Melanoma (Ocular)
This phase I trial is trying to understand how a new immunotherapy works, if it is safe and how well it is tolerated when it is given alone or in combination with another immunotherapy drug, in patients with HER2 cancers
This phase I trial is evaluating a new oral cancer drug in patients with select advanced solid cancers
This phase I/II trial is testing a new intravenous drug (THOR-707) as a monotherapy (alone) and in combination with an immunotherapy in adult patients with advanced cancer that has spread to other parts of the body
This phase I/II trial is exploring increasing doses of a new cancer drug (YH003) in combination with a targeted therapy with the aim of identifying and evaluating maximum tolerated/recommended dose
This phase I/II trial is evaluating the safety of a new oral drug using different dose levels, in patients with advanced solid cancer or Tenosynovial Giant Cell Tumor
This phase I trial will test how safe and tolerable a new oral cancer drug is for the treatment of patients with advanced solid cancers or cancers of the blood
This phase 1 trial is evaluating the effectiveness and safety of a novel immunotherapy (AK112) for the treatment of patients with advanced solid tumours
This phase I trial is evaluating ABBV-927 (an immunotherapy) alone and in combination with nivolumab for the treatment of advanced cancer
This phase I trial is evaluating a new targeted therapy in patients with advanced cancers and cancers that have spread to other parts of the body
This phase I/II trial is evaluating the safety and clinical activity of a new intravenous cancer treatment for people with high grade serous ovarian cancer or non-small cell lung cancer
This phase I trial is trying to understand if a new oral targeted therapy is safe and effective as a monotherapy or in combination with another cancer treatment in patients with advanced cancer
This phase I trial is evaluating an immunotherapy and chemotherapy combination in patients with advanced gastroesophageal cancer or colorectal cancer
This phase I/II trial is testing a new oral cancer drug (LOXO-292) for the treatment of children that have advanced solid- or primary central nervous system- cancer
This phase I/II trial is trying to understand how safe and tolerable a new immunotherapy is for the treatment of advanced cancer
This phase II trial is testing the effectiveness of a new oral drug (Pabinostat) in paediatric and adult patients who have an osteosarcoma, rhabdoid tumour and/or neuroblastoma that has gotten worse or not responded to prior treatment
This phase I trial is trying to understand whether a new intra-muscular treatment is safe and tolerable when given alone or in combination with immunotherapy for the treatment of small cell lung cancer, colorectal cancer or pancreatic cancer
This phase I trial is trying to understand whether a new intravenous drug is safe and tolerable for the treatment of patients with advanced cancer
This phase I trial is evaluating a new targeted therapy alone and in combination with another type of targeted therapy to see if it is safe and tolerable for advanced cancer patients
This Phase II trial is trying to determine whether using immunotherapy and radiotherapy for the treatment of localised, high-risk soft tissue sarcoma is more effective than giving radiotherapy alone
This phase I trial is trying to determine how safe and tolerable a new therapy (MGD013) is for treating patients with advanced cancers
This phase I trial is testing different chemotherapy and immunotherapy combinations in patients with advanced triple-negative breast cancer or ovarian cancer
This phase I trial is trying to understand if a new oral drug works and is safe for the treatment of advanced KRAS G12C mutated solid cancers that have spread to other parts of the body
This phase I trial is testing a new intravenous treatment for people with advanced solid cancers or B-cell lymphoma
This phase I trial is evaluating a new intravenous drug treatment in patients with cancers that express a specific gene (NaPi2b), in particular patients with ovarian cancer or non-small cell lung cancer
This phase Ib trial is trying to understand how safe and tolerable a type of targeted therapy is for the treatment of several different types of cancer
This phase I trial is evaluating a new intravenous drug (ARX788) in patients with HER2+ advanced cancers
This phase I trial is evaluating the safety and recommended dose of an immunotherapy drug alone and in combination for the treatment of patients with advanced solid cancers
This phase I trial is evaluating a new drug (GSK3359609) administered alone and in combination with an anticancer agent (pembrolizumab) for the treatment of advanced cancer
This Phase I trial is evaluating an intravenous drug (ABBV-321) in patients with advanced cancers that are associated with EGFR overexpression
This phase I trial is designed to evaluate the safety and maximum tolerated dose (MTD) of a new oral drug, given in combination with a type of immunotherapy in patients with solid cancers
This phase I/II trial is evaluating the combination of an oral drug (CBT-101) with two immunotherapy drugs (CBT-501 or Nivolumab) in patients with locally advanced or metastatic hepatocellular cancer (liver cancer) or renal cell carcinoma (a type of kidney cancer)
This phase I trial is trying to find the most suitable dose of an oral drug (GSK3368715) in patients who have a solid cancer type or a Diffuse Large B-Cell Lymphoma
This phase Ia/Ib trial is evaluating how safe, tolerable and effective a new targeted therapy is, given alone or in combination with another targeted therapy, in patients with advanced cancer
This phase I trial is trying to find a safe and tolerable dose of a new oral drug to treat patients diagnosed with advanced cancer, in particular patients with triple negative breast cancer, ovarian cancer and endometrial cancer
This phase I trial is trying to understand how safe and tolerable a new targeted therapy is (AK117) for the treatment of adults with advanced cancers that have spread to other parts of the body and have not responded/able to have other treatment
This phase I/II trial is evaluating a new type of immunotherapy, known as a neoantigen cancer vaccine, in combination with two established immunotherapies, as a treatment for several different types of cancer
This phase I/II trial is testing how safe and tolerable an immunotherapy is when given by itself or in combination with another standard type of immunotherapy (Nivolumab) in patients with advanced cancer
This phase I trial is testing a new oral drug in patients with advanced cancers (excluding some types of blood cancer)
This phase I/II trial is testing how safe and tolerable a new targeted cancer therapy is for the treatment of patients with mature B-cell blood cancer (when given in combination with the standard targeted therapy, zanubrutinib) or for patients with a type of advanced cancer (given in combination with the standard targeted therapy, tislelizumab)
This phase I trial is trying to determine the best dose of a drug (CC-95251) given to patients alone or in combination with one of two types of targeted cancer treatments (Rituximab or Cetuximab) in patients with advanced cancers (including advanced types of blood cancer)
This phase I trial is evaluating how safe and tolerable a new oral drug (IN10018) is, when it is given on it's own and in combination with an oral targeted therapy, for patients with uveal or NRAS-mutant melanoma that has spread to other parts of the body
This phase I/II trial is testing how safe ENB003 is as a treatment for select solid cancers, and how well it is tolerated in patients, when given alone or in combination with a type of immunotherapy (Pembrolizumab)
This phase I trial is testing a new drug on its own and in combination with a type of immunotherapy in patients with advanced cancers that have spread locally or to other parts of the body
This phase I trial is evaluating the combination of two targeted therapies (SAR439459 alone and in combination with Cemiplimab) in adult patients that have advanced solid cancers
This phase II trial is testing an oral targeted therapy (Erdafitinib) in patients diagnosed with an advanced cancer with changes to the FGFR gene
This phase I trial is trying to determine how safe and tolerable a new intravenous drug (RO7296682) is in treating patients with advanced solid cancers (excluding some types of blood cancer)
This phase 1 trial is evaluating the safety and effectiveness of a novel biological therapy (MK-0482) alone and in combination with a targeted therapy (pembrolizumab) to treat patients with advanced solid tumours
This phase II/III trial is comparing conventional radiotherapy and stereotactic radiotherapy in patients with spinal metastases
This phase 1 trial is examining the safety and effectiveness of two targeted therapies (BGB-A1217 and Tislelizumab) for the treatment of advanced solid tumours
This phase I/II immunotherapy trial is using a new drug (BMS-986205) in combination with Nivolumab and Ipilimumab for the treatment of cancers that are advanced or have spread
This phase I/II trial is evaluating the safety and activity of a new oral treatment (FLX475) alone and in combination with immunotherapy (Pembrolizumab) in patients with advanced cancer
This phase I trial is evaluating the effectiveness and safety of a targeted therapy (REGN3767) alone and in combination with another targeted therapy (Cemiplimab) for the treatment of patients with advanced cancer
This phase I/II trial evaluates the effectiveness, safety and tolerability of an immunotherapy (AGEN2034) for treatment of patients with metastatic or locally advanced solid tumours, and recurrent or metastatic cervical cancer that has progressed after chemotherapy
This phase I/II trial is trying to determine the safety and tolerability of an oral drug, repotrectinib
This phase I trial is evaluating an intravenous drug (PTX-100) in people with an advanced cancer
This phase I trial is evaluating a new immunotherapy drug (MK-7684) alone and in combination with another immunotherapy drug (Pembrolizumab) in patients with advanced solid tumours
This phase I trial is evaluating the safety and effectiveness of increasing doses of an immunotherapy drug (MK-1308) given in combination with another immunotherapy drug (Pembrolizumab) for the treatment of patients with advanced solid tumours
This phase I trial is evaluating the effectiveness, safety and tolerance for a targeted therapy (XNW7201) to treat patients with locally advanced or metastatic solid tumours.
This phase I trial is testing a new immunotherapy drug (Gevokizumab) in combination with other standard therapies for the treatment of colorectal cancers, gastroesophageal cancers and renal cell carcinomas that have spread to other parts of the body
This phase I/II trial is evaluating an oral drug (tazemetostat) alone and in combination with a steroid (prednisolone) for the treatment of advanced solid cancers and patients with B Cell Lymphoma
This phase I trial is evaluating a new biological therapy (AK-104) in adult patients with advanced solid cancers (excluding some blood cancers)
This phase I/II trial is evaluating the safety and effectiveness of an immunotherapy (Avelumab) when given in combination with a chemotherapy (gemcitabine / cisplatin) or another type of immunotherapy (pemetrexed / carboplatin) in the treatment of advanced cancer
This phase I trial is trying to determine the recommended dose of a new intravenous therapy (GSK3745417), when given alone or in combination with a type of immunotherapy, in patients with solid cancer types
This phase I/II trial is trying to determine whether it is safe to give the study drug (BMS-986249), alone and in combination with an immunotherapy (Nivolumab), to patients with advanced solid cancers
This early phase I trial is evaluating the safety and effectiveness of a new immunotherapy (Anti-B7-H4 Antibody, FPA150) alone and in combination with another type of immunotherapy (Pembrolizumab) in patients with select advanced cancers
This phase I/II trial is evaluating the safety and effectiveness of a combination treatment for patients with advanced pancreatic cancer or other EGFR expressing cancers
This phase I trial is testing a new drug (KN046) in patients with advanced cancers who are not able to have any other standard therapies
This phase I/II trial is evaluating the safety and recommended dose of a combined targeted therapy (BGB-A425 and Tislelizumab) in patients with advanced solid cancers
This phase I trial is assessing a new systemic therapy (LeY CAR-T cell therapy) in patients with solid cancers that express the LeY gene
This phase I trial is evaluating an oral drug (venetoclax) with or without chemotherapy in children and young adults with relapsed or refractory malignancies
This phase III trial is evaluating how well active surveillance and four different chemotherapy drugs (bleomycin, carboplatin, etoposide, or cisplatin) work in treating paediatric or adult patients with germ cell tumours
This Phase I/II trial is trying to determine the safety and recommended dose of two drugs (PD-0325901 and BGB-283) given in combination for the treatment of advanced solid cancers
This phase I trial is evaluating an intravenous drug (CK-301) in patients with select advanced cancers
This phase I trial is evaluating the safety and recommended dose of a new intravenous drug (FPT155) in patients with advanced solid cancers (except primary CNS cancers)
This phase I trial is looking at the effects of two immunotherapies (TetMYB Vaccine in combination with BGB-A317) in patients with advanced cancers ( including colorectal and adenoid cystic cancer) that may have spread to other parts of the body
This phase II trial is assessing a type of radiotherapy treatment for patients whose cancer has spread to the brain
This phase I trial is trying to find the optimal dose of an oral drug (AMG 510) to treat patients with advanced cancers with a specific KRAS mutation
This phase I trial is evaluating a new intravenous drug (NZV930) alone and in combination with two other drugs (one intravenous and one oral) for the treatment of specific advanced cancers
This phase I trial is evaluating a new biological therapy (MEDI5752) alone and in combination with various chemotherapy / immunotherapy drugs for the treatment of advanced solid cancers
This phase I trial is evaluating two drugs (MEDI94 and MEDI4736) alone and in combination for the treatment of adult patients with select solid cancers
This phase II trial is testing pembrolizumab (an immunotherapy drug) in patients with advanced cancers that have not responded (or worsened) on standard treatment
This phase I trial is evaluating a new oral drug (LOXO-292) in patients with Non-Small Cell (NSC) Lung Cancer, Medullary Thyroid Cancer (MTC) or another type of cancer with increased RET activity
This phase I trial is combining an oral drug (sitravatinib) with an immuno-oncology drug (Tislelizumab) for the treatment of patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC) or Ovarian Cancer (OC)
This phase I trial is evaluating a new intravenous drug (BTRC4017A) in patients with locally advanced or metastatic HER2-expressing cancers
This phase I trial is testing a new drug (HLX20) for people whose cancer has spread or come back following prior therapy
This phase I trial is combining two anti-cancer therapies (ABBV-181 and Rovalpituzumab Tesirine) in patients with advanced solid tumours
This phase II trial is evaluating an investigational drug (entrectinib) for the treatment of patients with solid cancers that express the NTRK1/2/3, ROS1 or ALK gene
This phase II trial is evaluating neratinib (targeted) therapy in patients that have solid cancers with activating HER2, HER3 or EGFR mutations
This phase I trial is evaluating an oral drug (dabrafenib) for children and adolescents with advanced BRAF V600-mutation positive cancers
This phase I trial is evaluating an intravenously (in the vein) administered drug (APG-1387) in patients with advanced solid cancers or Lymphoma
This phase III trial is evaluating pembrolizumab in patients who have previously received systemic treatment for advanced hepatocellular (liver) cancer
This phase III trial is comparing surgery alone and in combination with radiation therapy for the treatment of primary melanoma that has histoglogical features of neurotropism
This phase I trial is evaluating chemotherapy for the treatment of children with a cancer that has come back
This phase I/II trial is evaluating pembrolizumab (an immunotherapy drug) in children with advanced Melanoma, PD-L1 positive solid cancer or Lymphoma
Keyword Search
Cancer type
Trial type
Phase
Molecular targets
Tumour characteristics
Hospital
Alfred Hospital, Prahran
Ballarat Hospital, Ballarat
Ballarat Oncology & Haematology, Ballarat
Barwon Health, University Hospital Geelong, Geelong
Bendigo Hospital, Bendigo
Border Medical Oncology, Albury
Box Hill Hospital, Box Hill
Cabrini Hospital, Malvern
Epworth Freemasons, East Melbourne
Epworth Hospital, Richmond
Goulburn Valley Health, Shepparton
John Fawkner Hospital, Coburg
Maroondah Hospital, Maroondah Breast Clinic, Ringwood East
Mercy Hospital for Women, Heidelberg
Monash Health,
Northern Hospital, Epping
Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg
Peninsula & South Eastern Haematology and Oncology Group, Frankston
Peninsula Health, Frankston
Peninsula Private Hospital, Frankston
Peter MacCallum Cancer Centre, Moorabbin, Moorabbin
Peter MacCallum Cancer Centre, Box Hill
Peter MacCallum Cancer Centre, Melbourne
Peter MacCallum Cancer Centre Bendigo, Bendigo
Royal Childrens Hospital, Parkville
Royal Melbourne Hospital, Parkville
Royal Womens Hospital, Parkville
South West Healthcare, Warrnambool
St John of God, Geelong
St Vincent's Hospital, Fitzroy
Victorian Breast and Oncology Care, East Melbourne
Werribee Mercy, Werribee
Western Health - Sunshine Hospital, St Albans
Women's Health Research Program, Monash University, Alfred Hospital, Prahran
Use the search filters to narrow your search.
Don’t show me this again